Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
NCT00792506
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
1
Enrollment
INDUSTRY
Sponsor class
Stopped
The study was prematurely discontinued for lack of recruitement.
Conditions
Multiple Myeloma
Interventions
DRUG:
ITF2357
Sponsor
Italfarmaco